Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Acquired generalized lipodystrophy belongs to a group of lipodystrophic syndromes characterized by loss of adipose tissue, and is a syndrome of insulin resistance that leads to increased cardiovascular risk. Acquired generalized lipodystrophy is related to a selective loss of subcutaneous adipose tissue occurring exclusively at the extremities (face, legs, arms, palms and sometimes soles).
Estimated prevalence: Unknown (Unknown prevalence).
2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy. Pipeline includes 2 PHASE3. Research is primarily industry-sponsored.
17 publications have been identified in PubMed for acquired generalized lipodystrophy. Research spans Case Report / Case Series (47%), Review / Meta-Analysis (24%), and Epidemiology / Natural History (12%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 8 | 47% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 9:38 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acquired generalized lipodystrophy
Research summaries |
4 |
24% |
Disease patterns and progression | 2 | 12% |
New treatment approaches | 2 | 12% |
Laboratory research | 1 | 6% |
Letizia M (2026). [PMID: 41837291](https://pubmed.ncbi.nlm.nih.gov/41837291/). *J Clin Invest*. [Basic Science / Preclinical]
Vahidi Rad M (2026). [PMID: 41700130](https://pubmed.ncbi.nlm.nih.gov/41700130/). *JCEM case reports*. [Gene Therapy / Novel Therapeutics]
Quinn K (2026). [PMID: 29083781](https://pubmed.ncbi.nlm.nih.gov/29083781/). *Unknown Journal*. [Review / Meta-Analysis]
Barbosa R (2026). [PMID: 41869101](https://pubmed.ncbi.nlm.nih.gov/41869101/). *Cureus*. [Case Report / Case Series]
Kennedy R (2025). [PMID: 39935494](https://pubmed.ncbi.nlm.nih.gov/39935494/). *JCEM case reports*. [Case Report / Case Series]
Pliszka M (2025). [PMID: 40565151](https://pubmed.ncbi.nlm.nih.gov/40565151/). *International journal of molecular sciences*. [Review / Meta-Analysis]
Brown RJ (2025). [PMID: 40842493](https://pubmed.ncbi.nlm.nih.gov/40842493/). *Frontiers in endocrinology*. [Case Report / Case Series]
Al-Jawad M (2025). [PMID: 40154074](https://pubmed.ncbi.nlm.nih.gov/40154074/). *International journal of surgery case reports*. [Gene Therapy / Novel Therapeutics]
Brown RJ (2025). [PMID: 40469440](https://pubmed.ncbi.nlm.nih.gov/40469440/). *Frontiers in endocrinology*. [Case Report / Case Series]
Marsiglio J (2025). [PMID: 39704080](https://pubmed.ncbi.nlm.nih.gov/39704080/). *Melanoma research*. [Epidemiology / Natural History]